{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:15:37Z","timestamp":1780586137671,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01765-3","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T17:03:34Z","timestamp":1777741414000},"page":"3079-3105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding Social Drivers of Health, Burden, and Impact of Hidradenitis Suppurativa among Different Racial and Ethnic Groups in the USA"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2362-5121","authenticated-orcid":false,"given":"Tarannum","family":"Jaleel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Bacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Constantine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia R.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brindley","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candrice","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"4","key":"1765_CR1","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","volume":"149","author":"KR van Straalen","year":"2022","unstructured":"van Straalen KR, Prens EP, Gudjonsson JE. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022;149(4):1150\u201361.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1765_CR2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045\u201358.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1765_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ced.14826","volume":"47","author":"N Kashetsky","year":"2022","unstructured":"Kashetsky N, Mukovozov IM, Pereira J, Manion R, Carter S, Alhusayen R. Patient experiences with hidradenitis suppurativa: the Hidradenitis Patient Experience survey. Clin Exp Dermatol. 2022;47(1):72\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1765_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1159\/000525131","volume":"8","author":"AM Thompson","year":"2022","unstructured":"Thompson AM, Rick JW, De DR, et\u00a0al. Relationship disturbances in hidradenitis suppurativa: a patient perspective. Skin Appendage Disord. 2022;8(6):448\u201353.","journal-title":"Skin Appendage Disord"},{"issue":"8","key":"1765_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","volume":"153","author":"A Garg","year":"2017","unstructured":"Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760\u20134.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1765_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, et\u00a0al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2\u20133","key":"1765_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000477459","volume":"233","author":"RE Hunger","year":"2017","unstructured":"Hunger RE, Laffitte E, L\u00e4uchli S, et\u00a0al. Swiss Practice recommendations for the management of hidradenitis suppurativa\/acne inversa. Dermatology. 2017;233(2\u20133):113\u20139.","journal-title":"Dermatology"},{"issue":"1","key":"1765_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et\u00a0al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1765_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000503605","volume":"237","author":"AJ Hendricks","year":"2021","unstructured":"Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology. 2021;237(1):81\u201396.","journal-title":"Dermatology"},{"issue":"2_suppl","key":"1765_CR10","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1177\/12034754221116115","volume":"26","author":"LA Johnston","year":"2022","unstructured":"Johnston LA, Alhusayen R, Bourcier M, et\u00a0al. Practical guidelines for managing patients with hidradenitis suppurativa: an update. J Cutan Med Surg. 2022;26(2_suppl):2S-24S.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"1765_CR11","doi-asserted-by":"publisher","first-page":"2353693","DOI":"10.1080\/09546634.2024.2353693","volume":"35","author":"MT Eshmawi","year":"2024","unstructured":"Eshmawi MT, Yousef Al-Mudaiheem H, Fatani M, et\u00a0al. Expert consensus on unmet needs, referral criteria and treatment goals for hidradenitis suppurativa in Saudi Arabia. J Dermatol Treat. 2024;35(1):2353693.","journal-title":"J Dermatol Treat"},{"key":"1765_CR12","unstructured":"Centers for Medicare & Medicaid Services. Social Drivers of Health and Health-Related Social Needs. Available at: https:\/\/www.cms.gov\/priorities\/innovation\/key-concepts\/social-drivers-health-and-health-related-social-needs. Accessed February 24, 2025."},{"key":"1765_CR13","doi-asserted-by":"publisher","first-page":"1141051","DOI":"10.3389\/frma.2023.1141051","volume":"8","author":"J Doll","year":"2023","unstructured":"Doll J, Malloy J, Gonzales R. Social determinants of health: critical consciousness as the core to collective impact. Front Res Metr Anal. 2023;8:1141051.","journal-title":"Front Res Metr Anal"},{"key":"1765_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jdin.2021.01.007","volume":"3","author":"JM Kilgour","year":"2021","unstructured":"Kilgour JM, Li S, Sarin KY. Hidradenitis suppurativa in patients of color is associated with increased disease severity and healthcare utilization: a retrospective analysis of 2 U.S. cohorts. JAAD Int. 2021;3:42\u201352.","journal-title":"JAAD Int"},{"issue":"6","key":"1765_CR15","first-page":"613","volume":"114","author":"L Serrano","year":"2022","unstructured":"Serrano L, Ulschmid C, Szabo A, Roth G, Sokumbi O. Racial disparities of delay in diagnosis and dermatologic care for hidradenitis suppurativa. J Nat Med Assoc. 2022;114(6):613\u20136.","journal-title":"J Nat Med Assoc"},{"issue":"5","key":"1765_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/ijd.16428","volume":"62","author":"C Ulschmid","year":"2023","unstructured":"Ulschmid C, Serrano L, Wu R, Roth GM, Sokumbi O. African American race is a risk factor for severe hidradenitis suppurativa. Int J Dermatol. 2023;62(5):657\u201363.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1765_CR17","doi-asserted-by":"publisher","first-page":"e2024060","DOI":"10.5826\/dpc.1401a60","volume":"14","author":"K Roster","year":"2024","unstructured":"Roster K, Rajeh A, Lipner SR. Specialty utilization disparities among hidradenitis suppurativa patients in a retrospective analysis of the national ambulatory medical care survey 2006\u20132016. Dermatol Pract Concept. 2024;14(1):e2024060.","journal-title":"Dermatol Pract Concept"},{"issue":"6","key":"1765_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jaad.2017.10.001","volume":"77","author":"G Shalom","year":"2017","unstructured":"Shalom G, Babaev M, Freud T, et\u00a0al. Demographic and health care service utilization by 4417 patients with hidradenitis suppurativa. J Am Acad Dermatol. 2017;77(6):1047-52.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1765_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jaad.2022.09.054","volume":"88","author":"MR Nock","year":"2023","unstructured":"Nock MR, Barbieri JS, Krueger LD, Cohen JM. Racial and ethnic differences in barriers to care among US adults with chronic inflammatory skin diseases: a cross-sectional study of the all of us research program. J Am Acad Dermatol. 2023;88(3):568\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1765_CR20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/jvc2.409","volume":"3","author":"MT Polaskey","year":"2024","unstructured":"Polaskey MT, Chovatiya R. Understanding disparities in hidradenitis suppurativa through social and structural determinants of health. JEADV Clin Pract. 2024;3(4):945\u201361.","journal-title":"JEADV Clin Pract"},{"issue":"6","key":"1765_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archderm.1988.01670060015008","volume":"124","author":"TB Fitzpatrick","year":"1988","unstructured":"Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124(6):869\u201371.","journal-title":"Arch Dermatol"},{"key":"1765_CR22","unstructured":"Monk E (2019) Monk Skin Tone Scale"},{"issue":"10","key":"1765_CR23","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et\u00a0al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"3","key":"1765_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan G. Dermatology life quality index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1765_CR25","volume-title":"ECDEU assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health; 1976."},{"key":"1765_CR26","unstructured":"Centers NAoCH. Protocol for responding to and assessing patients\u2019 assets, risks, and experiences (PRAPARE) implementation and action toolkit. 2022."},{"key":"1765_CR27","unstructured":"All of Us Research Hub. Participant surveys: healthcare access & utilization."},{"issue":"8","key":"1765_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","volume":"155","author":"MO Machado","year":"2019","unstructured":"Machado MO, Stergiopoulos V, Maes M, et\u00a0al. Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(8):939\u201345.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1765_CR29","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1097\/JW9.0000000000000130","volume":"10","author":"FB Rinderknecht","year":"2024","unstructured":"Rinderknecht FB, Naik HB. Access to dermatologic care and provider impact on hidradenitis suppurativa care: global survey insights. Int J Womens Dermatol. 2024;10(1):e130.","journal-title":"Int J Womens Dermatol"},{"key":"1765_CR30","unstructured":"Mental Health Statistics (2024) 2024."},{"issue":"5","key":"1765_CR31","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg A, Neuren E, Abrouk M, et\u00a0al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the United States and Canadian hidradenitis suppurativa foundations. J Am Acad Dermatol. 2022;86(5):1097\u2013108.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1765_CR32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.36849\/JDD.7119","volume":"22","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Freese M, Saedi N, et\u00a0al. Barriers to dermatologic care and use of internet sources in hidradenitis suppurativa. J Drugs Dermatol. 2023;22(6):621\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1765_CR33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamadermatol.2023.0486","volume":"159","author":"LA Barnes","year":"2023","unstructured":"Barnes LA, Shukla N, Paul M, et\u00a0al. Patient perspectives of health system barriers to accessing care for hidradenitis suppurativa: a qualitative study. JAMA Dermatol. 2023;159(5):510\u20137.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1765_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et\u00a0al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91\u2013101.","journal-title":"J Am Acad Dermatol"},{"key":"1765_CR35","first-page":"1520","volume":"10","author":"FB Rinderknecht","year":"2023","unstructured":"Rinderknecht FB, Naik HB. Patient-perceived physician bias in hidradenitis suppurativa. J Racial Ethn Health Disparities. 2023;10:1520\u201331.","journal-title":"J Racial Ethn Health Disparities"},{"issue":"12","key":"1765_CR36","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/1346-8138.17386","volume":"51","author":"T Jaleel","year":"2024","unstructured":"Jaleel T, Mitchell B, Burge R, et\u00a0al. Exploring racial and ethnic disparities in the hidradenitis suppurativa patient disease journey: results from a real-world study in Europe and the USA. J Dermatol. 2024;51(12):1547\u201358.","journal-title":"J Dermatol"},{"issue":"4","key":"1765_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","volume":"56","author":"P Wolkenstein","year":"2007","unstructured":"Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1765_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13555-023-01085-w","volume":"14","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Kirby J, Ingram JR, et\u00a0al. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatol Ther (Heidelberg). 2024;14(1):83\u201398.","journal-title":"Dermatol Ther (Heidelberg)"},{"issue":"1","key":"1765_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jfma.2021.03.024","volume":"121","author":"B-J Hsieh","year":"2022","unstructured":"Hsieh B-J, Shen D, Hsu C-J, et\u00a0al. The impact of atopic dermatitis on health-related quality of life in Taiwan. J Formosan Med Assoc. 2022;121(1):269\u201377.","journal-title":"J Formosan Med Assoc"},{"issue":"4","key":"1765_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.det.2024.04.005","volume":"42","author":"W Fitzmaurice","year":"2024","unstructured":"Fitzmaurice W, Silverberg NB. Long-term impact of atopic dermatitis on quality of life. Dermatol Clin. 2024;42(4):549\u201357.","journal-title":"Dermatol Clin"},{"issue":"7","key":"1765_CR41","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/ijd.13601","volume":"56","author":"S Hessam","year":"2017","unstructured":"Hessam S, Salem J, Bechara FG, et\u00a0al. Hidradenitis suppurativa gains increasing interest on World Wide Web: a source for patient information? Int J Dermatol. 2017;56(7):726\u201332.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1765_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ijwd.2021.02.005","volume":"7","author":"NR Shukla","year":"2021","unstructured":"Shukla NR, Jia JL, Paul M, Kaghazchi A, Linos E, Naik HB. Quality and engagement of online hidradenitis suppurativa information. Int J Womens Dermatol. 2021;7(4):490\u20131.","journal-title":"Int J Womens Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01765-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01765-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01765-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:37Z","timestamp":1780584817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01765-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1765"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01765-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tarannum Jaleel has received research grants from UCB, Skin of Color Society, Dermatology Foundation, Duke Strong Start Award, Duke Precisions Genomics Collaboratory Pilot Grant, NIH BIRCWH from NIAMS K12AR084231. She has also received speaker honorarium from PeerView, consulting fees from Novartis, Eli Lilly, and travel funds to attend meetings from Skin of Color Society, and IDEOM. She is also associated with the Skin of Color Society in a leadership or fiduciary role within other boards, societies, committees, or advocacy groups, whether compensated or not. Raj Chovatiya has received consulting fees from AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics Inc., Argenx, Astria Therapeutics Inc., Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Galderma, Genentech, GSK, Incyte, Johnson & Johnson, Kenvue, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, UCB, and Zai Lab; Raj Cjovatiya is an Editorial Board member of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for this manuscript or any subsequent editorial decisions. Elizabeth D. Bacci, Melissa L. Constantine, and Julia R. Correll are employees of Evidera. Evangeline Pierce, Beth Mitchell, and Dipak R. Patel are employees and stockholders of Eli Lilly and Company. Brindley Brooks declared no competing interests. Candrice Heath has received consulting fees from Proctor and Gamble, Johnson and Johnson, Tower28, L\u2019Oreal, WebMD, Kenvue, Arcutis, Lilly, Apogee, Nutrafol, Dermavant, and Unilever. Her university has received research grant funds from Robert A. Winn Excellence in Clinical Trials Award and Skin of Color Society. The affiliation of Candrice Heath has changed since this research was conducted and the manuscript was submitted to the journal. The author\u2019s current affiliation is the Department of Dermatology, Howard University College of Medicine, Washington, D.C., USA. Vivian Y Shi has received speaker honorarium from Novartis, Sanofi-Regeneron, AbbVie, consulting fees from Novartis, Eli Lilly, and consulting fees from AbbVie, Almirall, Alumis, Aristea Therapeutics, Dermavant, Boehringer-Ingelheim, Apogee, Eli Lilly, Galderma, Genentech, Incyte, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB, and Ceraclere.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Advarra institutional review board (Pro00070530), conducted in accordance with the ethical principles in the Declaration of Helsinki, and consistent with Good Pharmacoepidemiology Practices, as well as applicable laws and regulations, as appropriate. Participants provided authorization for the use and disclosure of their personal health information, including the collection and release of data on treatment and outcomes throughout the study period. Confidentiality of participant information was maintained throughout the study. All recruitment procedures complied with current Health Insurance Portability and Accountability Act regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}